Other phase Ib/II clinical trials are evaluating the efficacy of olaparib in combination with capivasertive (AKT inhibitor) or vistusertib (mTORC1/2 inhibitor) in BRCA1/2-mutated recurrent endometrial and ovarian cancer (NCT02208375). This evidence concerns the gene BRCA1 and ovarian cancer.